Readystate Asset Management LP Takes $1.06 Million Position in Replimune Group, Inc. $REPL

Readystate Asset Management LP acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL) during the first quarter, Holdings Channel.com reports. The firm acquired 138,488 shares of the company’s stock, valued at approximately $1,059,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. ProShare Advisors LLC boosted its position in Replimune Group by 10.3% during the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock worth $157,000 after purchasing an additional 1,505 shares during the period. JPMorgan Chase & Co. increased its position in Replimune Group by 4.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock worth $159,000 after buying an additional 1,712 shares during the period. Ballentine Partners LLC lifted its holdings in shares of Replimune Group by 7.8% during the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock worth $230,000 after buying an additional 1,721 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares during the period. Finally, Walleye Capital LLC grew its stake in shares of Replimune Group by 3.2% in the first quarter. Walleye Capital LLC now owns 71,592 shares of the company’s stock worth $548,000 after acquiring an additional 2,192 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group News Roundup

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Trading activity has been unusually heavy, suggesting investors are repositioning ahead of the FDA’s upcoming advisory committee meeting. The current move appears more consistent with volatility and a potential rebound after the prior selloff than with a new fundamental catalyst.
• Negative Sentiment: FDA staff reviewers questioned whether Replimune’s RP1 therapy has demonstrated sufficient efficacy in advanced melanoma. The concerns have raised expectations that the agency could reject or delay approval, making the advisory committee meeting a major near-term risk for REPL. Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy
• Negative Sentiment: Multiple law firms—including Kirby McInerney, Glancy Prongay Wolke & Rotter, and Howard G. Smith—announced investigations into whether Replimune or its executives violated securities laws or made misleading disclosures. These announcements do not establish wrongdoing, but they add legal and reputational overhang and could potentially lead to shareholder claims. Kirby McInerney investigation announcement
• Negative Sentiment: The investigations follow the FDA briefing-document disclosure that prompted a major one-day decline in REPL shares, as investors reassessed the probability of RP1 approval and the value of Replimune’s pipeline. Replimune shares fall on negative FDA comments

Replimune Group Price Performance

NASDAQ:REPL opened at $5.41 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The company has a 50-day moving average of $9.35 and a 200-day moving average of $7.37. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $12.50. The company has a market capitalization of $454.12 million, a price-to-earnings ratio of -1.60 and a beta of 0.86.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). As a group, equities research analysts anticipate that Replimune Group, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

REPL has been the topic of a number of research reports. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research note on Friday, April 10th. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Weiss Ratings upgraded shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Finally, Wedbush upped their price objective on shares of Replimune Group from $6.00 to $9.00 and gave the company a “neutral” rating in a research report on Tuesday, June 30th. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.86.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.